| Meeting Brochure and registration form SMDM Homepage | |
|
|
|
||||
| Sunday, 15 October 2006: 6:30 PM-8:30 PM | |||
| Riverside (Hyatt Regency Cambridge) | |||
| Poster Session I | |||
| 1 | CALCULATION OF PREVALENCE-BASED ECONOMIC EVALUATION OF THROMBOLYSIS FOR STROKE THROUGH MARKOV MODELS Javier Mar, MD, PhD, Maria Sainz-Ezkerra, MSc | ||
| 2 | MARK VERSUS LUKE? DECISION MAKING WITH MULTIPLE OBJECTIVES AND MULTIPLE CONSTRAINTS Karl Claxton, PhD, MSc, BA, Mark Sculpher, PhD, Anthony J. Culyer | ||
| 3 | COMPARISON OF TWO METHODS FOR ESTIMATING THE VALUE OF PATIENT TIME SPENT IN SCREENING COLONOSCOPY Daniel E. Jonas, MD, Louise B. Russell, PhD, Robert Sandler, MD, MPH, Justin Chou, BS, Michael Pignone, MD, MPH | ||
| 4 | DANGEROUS OMISSIONS: THE OPPORTUNITY COSTS OF DECISION UNCERTAINTY Susan Griffin, MSc, BSc, Karl Claxton, PhD, MSc, BA, Stephen Palmer, Mark Sculpher | ||
| 5 | ANALYSIS OF POST-TREATMENT SURVIVAL DATA M. P. Janssen, MSc, Cees P. van der Poel, MD, PhD, Wim P. Schaasberg, MSc, Gouke J. Bonsel, MD, PhD, Ben A. van Hout, PhD | ||
| 6 | BETTER MODELING TECHNIQUES, BETTER MODELS? Karen M. Lee, MA, Braden Manns, MD, MSc | ||
| 7 | QUALITY OF CLINICAL EVIDENCE IN ECONOMIC EVALUATIONS Karen M. Lee, MA, Vijay K. Shukla, RPh, PhD, Mike Tierney, RPh, MSc | ||
| 8 | USING THE NET BENEFIT REGRESSION FRAMEWORK TO ANALYZE PERSON-LEVEL OBSERVATIONAL DATA Jeffrey Hoch, PhD, David O. Meltzer, MD, PhD | ||
| 9 | EXERCISE PROGRAMS FOR TYPE 2 DIABETES: AN ECONOMIC ANALYSIS Douglas Coyle, PhD, Kathryn O'Grady, MSc, Penny Phillips, Glen Kenny, PhD, Ronald J. Sigal, MD, MPH | ||
| 10 | A PHYSICIAN SURVEY TO ELICIT THE NET CONSEQUENCE RATIO FOR THE DECISION TO ADMIT PATIENTS WITH SUSPECTED ACUTE CORONARY SYNDROME Stewart S. Worrell, MD, MPH, J. Tobias Nagurney, MD, MPH, Udo Hoffmann, MD, Scott Gazelle, Uwe Siebert, MD, MPH, MSc | ||
| 11 | *VALUING CHILDREN'S HEALTH: A COMPARISON OF COST-UTILITY ANALYSES FOR ADULT AND PEDIATRIC HEALTH INTERVENTIONS Joseph A. Ladapo, BA, Peter Neumann, ScD, Lisa A. Prosser, PhD | ||
| 12 | *SCREENING STRATEGIES OVERRATED FOR DISEASES WITH UNCERTAIN PROGRESSION H. Koffijberg, E. Buskens | ||
| 13 | *EFFECT OF TIME HORIZON ON INCREMENTAL COST-EFFECTIVENESS RATIOS: HOW LONG DO WE COUNT? Manu Sondhi, MD, MBA, John Wong, MD, Stephen G. Pauker, MD | ||
| 14 | *ECONOMIC METHODS IN BUDGETARY IMPACT ANALYSIS: A CRITICAL REVIEW Bohdan Nosyk, MA, Nick J. Bansback, MSc, Xin Li, PhD, Daphne P. Guh, MSc, Huiying Sun, PhD, Aslam H. Anis, PhD | ||
| 15 | A COMPARISON OF NET BENEFITS OF THREE STRATEGIES FOR THE SURGICAL TREATMENT OF SYMPTOMATIC PRIMARY HYPERPARATHYROIDISM (HPT) Chris R. Baliski, MD, FRCSC, Bohdan Nosyk, MA, Adrienne Melck, MD, Samuel P. Bugis, MD, FRCSC, Frances Rosenberg, MD, PhD, FRCPC, Aslam H. Anis, PhD | ||
| 16 | DIGITAL VERSUS PLAIN-FILM MAMMOGRAPHY: A COST-EFFECTIVENESS ANALYSIS Anupam Goel, MD, Robert C. Burack, MD, MPH | ||
| 17 | ARE SINGLE USE INSTRUMENTS COST-EFFECTIVE IN STOPPING IATROGENIC VCJD TRANSMISSION? Matt Stevenson, PhD, Jeremy E. Oakley, PhD, Stephen E. Chick, PhD, Kalipso Chalkidou | ||
| 18 | COST-EFFECTIVENESS OF TARGETING BREAST CHEMOTHERAPY BASED ON A 21-GENE ASSAY Richard Orr, MD, MPH, R. Barry Hird, MD | ||
| 19 | A COST-EFFECTIVENESS ANALYSIS OF MAMMOGRAPHY SCREENING IN HONG KONG Irene O. L. Wong, MPH, MPhil, BSc, Karen M. Kuntz, ScD, Benjamin J. Cowling, PhD, Cindy L. K. Lam, MD, Gabriel M. Leung, MD | ||
| 20 | COST EFFECTIVENESS OF STRATEGIES FOR THE LONG TERM FOLLOW UP FOR EARLY STAGE BREAST CANCER Douglas Coyle, PhD, Kathryn O'Grady, MSc, Jim A. Julian, MMath, Barbara Szechtman, BA, Mark Levine, MD, MSc, Eva Grunfeld, MD, DPhil | ||
| 21 | MODELING LONG-TERM COST EFFECTIVENESS OF ENTECAVIR IN SUPPRESSING VIRAL REPLICATION TO UNDETECTABLE GOAL IN CHRONIC HEPATITIS B PATIENTS Yong Yuan, PhD, Joel Hay, PhD, Uchenna Iloeje | ||
| 22 | IS NEWBORN SCREENING FOR MEDIUM CHAIN ACYL~COA DEHYDROGENASE DEFICIENCY (MCADD) USING TANDEM MASS SPECTROMETRY (MS/MS) COST EFFECTIVE FOR ALL JURISDICTIONS IN CANADA? Huimin Li, MA, Khai Tran, PhD, Srabani Banerjee, PhD, Hussein Noorani, MSc, Shaila Mensinkai, MA, MLIS, Kent Dooley, PhD, FCACB | ||
| 23 | RADIOFREQUENCY ABLATION VERSUS SURGERY FOR SMALL, UNILATERAL RENAL CELL CARCINOMA: A COST-EFFECTIVENESS ANALYSIS Pari V. Pandharipande, MD, MPH, Debra A. Gervais, MD, Peter R. Mueller, MD, Chin Hur, MD, MPH, G. Scott Gazelle, MD, MPH, PhD | ||
| 24 | COST-EFFECTIVENESS OF INTERVENTIONS FOR THE PREVENTION AND CONTROL OF DIABETES: A SYSTEMATIC REVIEW Rui Li, Ph.D., Farah Chowdhury, MBBS, MPH, Ping Zhang, PhD, Xuanping Zhang, PhD | ||
| 25 | ADJUSTING FOR CROSSOVERS IN RANDOMIZED TRIALS USING MARGINAL STRUCTURAL MODELS IN COST-EFFECTIVENESS ANALYSIS D. Mkaya Mwamburi, Christine Wanke, John L. Griffith, Ira B. Wilson, Peter J Neumann, John B. Wong, MD | ||
| 26 | COST-EFFECTIVENESS OF EXTENDED SCREENING PROGRAMS FOR SECONDARY PREVENTION OF CARDIOVASCULAR DISEASE Iris De kruif, Msc, E. Buskens | ||
| 27 | COST EFFECTIVENESS OF STANOL ESTERS ENRICHED MARGARINE Iris De kruif, Msc, Ben Van Hout, PhD | ||
| 28 | COST-EFFECTIVENESS OF CINACALCET FOR THE TREATMENT OF SECONDARY HYPERPARATHYROIDISM IN END-STAGE RENAL DISEASE: A BAYESIAN MARKOV MODEL George Tomlinson, PhD, Andreas Maetzel, MD, MSc, PhD | ||
| 29 | A COST EFFECTIVENESS ANALYSIS OF TREATMENT STRATEGIES INCLUDING TUMOR NECROSIS FACTOR INHIBITORS AND ABATACEPT FOR PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS Khalid M. Kamal, PhD, Lesley-Ann N. Miller, PhD, MS | ||
| 30 | COSTS OF VOLUNTARY HIV TESTING IN SELECTED COUNTY JAILS IN THE UNITED STATES Ram K. Shrestha, PhD, Stephanie Sansom, PhD, April L. Richardson-Moore, RN, MPH, Tyler French, Beth Scalco, Marlene LaLota, Miche Llanas, James Stodola, Robin MacGowan, MPH, Andrew Margolis, MPH | ||
| 31 | DESIGNING ECONOMIC EVALUATIONS IN LATE-STAGE HIV: WHAT HEALTH STATES SHOULD BE INCLUDED? Huiying Sun, PhD, Daphne P. Guh, MSc, Nick J. Bansback, MSc, Bohdan Nosyk, MA, Xin Li, PhD, William Cameron, MD, Sheldon Brown, MD, Brian Gazzard, MD, Douglas K. Owens, MD, MS, Mark Sculpher, PhD, Joel Singer, PhD, Martin Schechter, MD, PhD, Aslam H. Anis, PhD | ||
| 32 | COST-EFFECTIVENESS OF ELDERLY HEALTH EXAMINATION PROGRAM (EHEP): THE EXAMPLE OF HYPERTENSION SCREENING Herng-Chia Chiu, PHD, Bing-Hwa Deng, MHA, Hong-Wen Liu, MD, Pi-Chen Pan, PHD, Lih-Wen Mau, PHD | ||
| 33 | *IS UNICOMPARTMENTAL KNEE ARTHROPLASTY A COST-EFFECTIVE ALTERNATIVE TO TOTAL KNEE ARTHROPLASTY IN THE ELDERLY LOW-DEMAND PATIENT POPULATION? James Slover, MD, MS, Ivan Tomek, MD, OVE Furnes, MD, PhD, Anna N.A. Tosteson, ScD | ||
| 34 | *COST-EFFECTIVENESS OF IMAGING STRATEGIES FOR DETERMINING DIAGNOSIS AND ASSESSING RESECTABILITY IN PATIENTS WITH SUSPECTED PANCREATIC CANCER Tania Schink, Dipl.-Stat., Michael Böhmig, MD, Jaqueline Müller-Nordhorn, Dr.med, DPH, Chin Hur, MD, MPH, Inga Koch, MD, Klaus-Dieter Wernecke, Prof., Uwe Siebert, MD, MPH, MSc | ||
| 35 | *COST-EFFECTIVENESS OF EARLY TREATMENT FOR RETINOPATHY OF PREMATURITY Karen L. Kamholz, MD, MPH, Cynthia H. Cole, MD, MPH, John A.F. Zupancic, MD, ScD | ||
| 37 | *COST-UTILITY ANALYSIS OF TRANSFERRING ONE THROUGH FIVE EMBRYOS PER IN VITRO FERTILIZATION CYCLE Sarah Little, AB, Jennifer Ratcliffe, MD, PhD, Aaron B. Caughey, MD, MPP, MPH | ||
| 38 | *COST-EFFECTIVENESS OF ADDING THE SERUM CDT TEST TO QUESTIONNAIRE BASED SCREENING FOR AT-RISK DRINKING AMOUNTS IN THE PRIMARY CARE SETTING Alok Kapoor, MD, Kevin L. Kraemer, MD, MSc, Mark S. Roberts, MD, MPP, Rich Saitz, MD, MPH | ||
| 39 | *COST-EFFECTIVENESS OF HELICOBATER PYLORI SCREENING TO PREVENT GASTRIC CANCER IN A HIGH-RISK REGION OF CHINA Jennifer M. Yeh, MS, Karen M. Kuntz, ScD, Majid Ezzati, PhD, Sue J. Goldie, MD, MPH | ||
| 40 | *COST-EFFECTIVENESS OF A ROTAVIRUS VACCINATION PROGRAM IN INDIA Johnie Rose, MD, Rachel Molnar, Brook Watts, MD, Mendel E. Singer, PhD | ||
| 41 | *A COST-EFFECTIVENESS ANALYSIS OF FOLIC ACID FORTIFICATION POLICY IN THE UNITED STATES Tanya G.K. Bentley, Ph.D., Milton C. Weinstein, PhD, Walter C. Willett, M.D., Dr.P.H., Karen M. Kuntz, ScD | ||
| 42 | *COST-EFFECTIVENESS OF ALTERNATIVE SCREENING STRATEGIES FOR OSTEOPOROSIS IN POSTMENOPAUSAL WOMEN Smita Nayak, MD, Hau Liu, MD, MBA, MPH, Kaleb Michaud, MS, Douglas K. Owens, MD, MS | ||
| 43 | INSTITUTIONAL PATIENT SAFETY LEVELS AMONG THE HEALTHCARE'S “MOST WIRED” HOSPITALS Feliciano B. Yu Jr., MD, MSHI, MSPH, Thomas K. Houston, MD, MPH | ||
| 44 | A MODEL OF HEALTH NUMERACY: HOW PATIENTS USE QUANTITATIVE SKILLS IN HEALTH CARE Marilyn Schapira, MD, MPH, Alex Matthews, PhD, Mary Ann Gilligan, Toni Laforest, MBA, Joan Neuner, Prakash Laud, Ph.D., Elizabeth Hayes, PhD | ||
| 45 | A RANDOMIZED CONTROLLED TRIAL OF A COMPUTER-BASED HORMONE THERAPY DECISION-AID Marilyn Schapira, MD, MPH, Mary Ann Gilligan, MD, MPH, Timothy McAuliffe, Gwenn Garmon, MD, Molly Carnes, MD, Ann B Nattinger | ||
| 47 | VALIDATION OF AN ASTHMA COMPUTERIZED DECISION SUPPORT SYSTEM Thomas Stern, MD, MS, Asha Garg, MD, MPH, Neal V. Dawson, MD, Nancy Messina, RRT, E. Regis McFadden, MD | ||
| 48 | TRIAL ROULETTE: A SIMPLE WAY TO ELICIT SUBJECTIVE PROBABILITY DISTRIBUTIONS? Tim Rakow, Anthony O'Hagan, Caitlin Buck | ||
See more of The 28th Annual Meeting of the Society for Medical Decision Making (October 15-18, 2006)
Papers submitted for the Lee B. Lusted Student Prize Competition are denoted with an asterisk (*)